• Journal of Veterinary Clinics
• /
• v.24 no.3
• /
• pp.392-399
• /
• 2007

Scutellaria baicalensis Georgi. (SBGE) is known to be antioxidant effect. In addition of the effects, we further investigated the SBGE on the antioxidant effect on a renal cortical slices cell and kidney protecting effects. The results were as follows. 1 When renal cortical slices separated from a rabbit's kidney were treated with 1mM tert-Butylhydroperoxide (t-BHP) in the presence of SBGE. SBGE significant prevented t-BHP induced increase in lactate dehydrogenase (LDH) release and lipid peroxidation. 2. When renal cortical slices separated from a rabbit's kidney were treated with oxidant $300{\mu}M$ cisplatin in the presence of SBGE. SBGE significant prevented cisplatin-induced increase in LDH release and lipid peroxidation. 3. Pretreatment with 0.1g/kg SBGE for seven day and treatment with 5 mg/kg cisplatin by the intraperitoneal injection The results were that the pretreatment group with SBGE showed a significant decrease in lipid peroxidation, increase in clearance rate of blood urea nitrogen (BUN) and creatinine in the kidney than the administering single agent group of cisplatin. and pretreatment group with SBGE showed intact microvillus of proximal tubule and no contraction of rumen, it was a similar result with normal group. With the results SBGE showed to be highly effective on antioxidant effect and cellular protection activity against cisplatin that was a toxic agent on a kidney. Therefore, SBGE is considered to have protective effective on a disordered kidney or kidney diseases such as nephritis or renal failure that cause tissue damages in a kidney.

• The Journal of Internal Korean Medicine
• /
• v.21 no.2
• /
• pp.227-234
• /
• 2000

독성약물에 의한 급성신부전시 세뇨관세포의 물질 재흡수 장애에 대한 단삼(丹參) 추출액의 효과를 조사하였다. 토끼에 수은(HgCl2)을 10 mg/kg되게 피하 주사하여 급성신부전을 유발하였고, 단삼(丹參) 추출액의 효과는 수은을 주사하기 전 7일 동안 0.05% 액(液) 0.3 g/kg 용량을 경구 투여하여 관찰하였다. 수은을 주사하기 전 24시간 동안 요와 혈액을 채취하여 신장기능을 측정하여 대조기간(basal period)의 값으로 하였고, 수은을 주사한 후 24시간 동안 요와 혈액을 얻어 수은에 의한 신장기능 변화를 평가하였다. 수은을 처리한 후 사구체여과율이 대조값에 비해 감소하였고, 혈청내 creatinine 농도가 증가하였다. 이러한 결과들은 수은이 급성신부전을 유발하였음을 가리킨다. 수은을 처리한 동물에서 포도당 및 인산의 배설분율이 증가하였고, 이러한 변화는 brush-border membrane에서 물질의 이동장애와 Na-pump 활성의 감소에 기인하였다. 수은을 주사한 동물의 신장피질 절편에서 유기이온인 PAH와 TEA 이동이 억제되었다. 토끼의 신장조직에서 지질의 과산화가 수은을 주사한 후 증가하였다. 단삼(丹參) 추출액을 전 처리한 후 수은을 주사한 경우 수은에 의해 유발된 사구체여과율의 감소와 혈청내 creatinine 농도 증가 현상이 유의하게 완화되었다. 수은에 의한 세뇨관에서 물질의 재흡수 장애가 단삼(丹參) 추출액의 전처리에 의해 방지되었다. 단삼(丹參) 추출액은 수은에 의한 지질의 과산화를 억제하였다. 수은에 의한 급성신부전은 항산화제로 잘 알려진 DPPD에 의해 방지되었다. 이상의 결과를 종합하면 생체실험결과 수은에 의한 급성신부전의 유발과정에 지질의 과산화가 중요한 역할을 할 가능성을 보이고 있고, 단삼(丹參) 추출액은 수은에 의한 급성신부전을 방지하는 효과를 가지고 있으며, 그 효과는 단삼(丹參)의 항산화작용에 기인(起因)할 가능성이 많다.

• Biomolecules & Therapeutics
• /
• v.6 no.2
• /
• pp.171-181
• /
• 1998

DA-3585, a biosynthetic recombinant human erythropoietin has been developed as a treatment for anemia associated with chronic renal failure in Dong-A pharmaceutical Co. Ltd. This study was carried out to assess its acute and subacute toxicities in rabbits. DA-3585 was intravenously administered to rabbits at dose levels of 6250, 12500 or 25000 lU/kg for single dose toxicity study and at dose levels of 100, 500 or 2500 lU/kg/day for 4-week repeated dose toxicity study. In the acute toxicity study, dose up to 25000 lU/kg had no adverse effect on the behavior or body weight gain. Pathological examinations revealed no abnormal gross lesions related to DA-3585. In the subacute toxicity study, all animals survived until termination of treatment. DA-3585 had no influence on clinical signs, food and water intake or on body weight changes. Hematological examination showed increases in the number of RBC, hemoglobin contents and hematocrit values with a dose dependent manner in the animals treated with DA-3585. Histopathological examination revealed erythroid hyperplasia in the bone marrow and extramedullary hematopoiesis in the liver. The changes detected in the hematological and histopathological examination presumably represent exaggerated pharmacological effects of erythropoietin. The NOAEL (no-observed-adverse-effect-level) of DA-3585 was estimated to be 100 lU/kg/ day under this study condition.

• Journal of Life Science
• /
• v.24 no.7
• /
• pp.777-783
• /
• 2014

Cathepsin D (CtsD), an aspartyl peptidase, is involved in apoptosis, resulting in the release of cytochrome C from mitochondria in cells. Here, we investigated microRNA regulation of CtsD expression in 3T3-L1 cells. First, we observed the expression of CtsD in cells in response to doxorubicin (Dox). As expected, the level of CtsD mRNA increased in 3T3-L1 cells exposed to Dox in a dose-dependent manner. The cellular viability of ectopically expressed CtsD cells was decreased. Next, we used the miRanda program to search for particular microRNA targeting CtsD. MiR-145 was selected as a putative controller of CtsD because it had a high mirSVR score. In a reporter assay, the luciferase activity of cells containing the CtsD 3'-UTR region decreased in cells transfected with a miR-145 mimic compared to that of a control. The level of CtsD expression was down-regulated in preadipocytes ectopically expressing miR-145 and up-regulated by an miR-145 inhibitor. Cells also suppressed miR-145 expression when exposed to Dox. The miR-145 inhibitor reduced the cellular viability of 3T3-L1 cells. Taken together, these data suggest that miR-145 regulates CtsD-mediated cell death in adipocytes. These findings may have valuable implications concerning the molecular mechanism of CtsD-mediated cell death in obesity, suggesting that CtsD could be a useful therapeutic tool for the prevention and treatment of obesity by regulating fat cell numbers.